Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5186811 | 0.99 | PTGS2 (0.97) | PTGS2PTGS1 | |
| SCHEMBL2126159 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL8068392 | 0.86 | PTGS2 (0.76) | PTGS2PTGS1 | |
| SCHEMBL4575048 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL4576392 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5185782 | 0.86 | PTGS2 (0.75) | PTGS2PTGS1 | |
| SCHEMBL8397305 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL8724654 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL8070399 | 0.85 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL2125484 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303265-B1 | USE OF COX-2 INHIBITORS AS IMMUNOSTIMULANTS IN THE TREATMENT OF HIV OR AIDS | LAURAS AS (NO) | 2007-07-11 | — | — | EP | claimed |
| US-20060154954-A1 | Combinations and use of selected pharmaceutically active compounds | ALTANA PHARMA AG (DE) | 2006-07-13 | — | — | US | claimed |
| EP-1599175-A2 | IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS | ALTANA Pharma AG (DE) | 2005-11-30 | — | — | EP | claimed |
| WO-2005074930-A1 | PHARMACEUTICAL COMBINATIONS OF (S) -PANTOPRAZOLE WITH NSAID OR CORTICOSTEROIDS | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | claimed |
| US-20050075359-A1 | Large conductance calcium-activated K channel opener | TANABE SEIYAKU CO., LTD. (JP) | 2005-04-07 | — | — | US | claimed |
| WO-2004071391-A2 | IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS | ALTANA PHARMA AG (DE) | 2004-08-26 | — | — | WO | claimed |
| EP-1400243-A1 | Calcium-activated K channel activator | TANABE SEIYAKU CO., LTD. (JP) | 2004-03-24 | — | — | EP | claimed |
| EP-1239879-B1 | FORMULATIONS OF ADENOSINE A1 AGONISTS AND COX2-INHIBITORS | GLAXO GROUP LTD (GB) | 2004-02-25 | — | — | EP | claimed |
| US-20250339458-A1 | USES OF MODIFIED RNA ENCODING RETINALDEHYDE DEHYDROGENASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250144227-A1 | C-16 MODIFIED TRIOXACARCINS, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-05-08 | — | — | US | disclosed |
| US-20240148889-A1 | STABILIZED TRIOXACARCIN ANTIBODY DRUG CONJUGATES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-05-09 | — | — | US | disclosed |
| WO-2023096904-A2 | C-16 MODIFIED TRIOXACARCINS, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2021252708-A1 | STABILIZED TRIOXACARCIN ANTIBODY DRUG CONJUGATES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20210338709-A1 | USES OF MODIFIED RNA ENCODING RETINALDEHYDE DEHYDROGENASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-04 | — | — | US | disclosed |
| US-20040082640-A1 | Use of cox-2 inhibitors for preventing immunodeficiency | LAURAS AS (NO) | 2004-04-29 | — | — | US | disclosed |
| US-20030114444-A1 | [[2-(Amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain | WYETH | 2003-06-19 | — | — | US | disclosed |
| WO-2003048122-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-1303265-A2 | USE OF COX-2 INHIBITORS FOR PREVENTING IMMUNODEFICIENCY | Lauras AS (NO) | 2003-04-23 | — | — | EP | disclosed |
| WO-2003031416-A2 | [[2-(AMINO-3,4-DIOXO-1CYCLOBUTEN-1-YL)AMINO]ALKYL]-ACID DERIVATIVES FOR THE TREATMENT OF PAIN | WYETH (US) | 2003-04-17 | — | — | WO | disclosed |
| WO-2002007721-A2 | USE OF COX-2 INHIBITORS FOR PREVENTING IMMUNODEFICIENCY | LAURAS AS (NO) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148889-A1 | STABILIZED TRIOXACARCIN ANTIBODY DRUG CONJUGATES AND USES THEREOF | ABCB4, PCSK7, F12 | PTGS2 4570/4885PTGS1 4271/4885 |
| US-20250144227-A1 | C-16 MODIFIED TRIOXACARCINS, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | UGT2B17, ABCB4, IL17A | PTGS2 4770/4885PTGS1 4813/4885 |
| US-20030114444-A1 | [[2-(Amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain | OPRD1, OPRL1, OPRK1 | PTGS2 111/4885PTGS1 116/4885 |
| US-20050075359-A1 | Large conductance calcium-activated K channel opener | KCNN3, KCNN2, KCNN1 | PTGS2 806/4885PTGS1 760/4885 |
| US-20040082640-A1 | Use of cox-2 inhibitors for preventing immunodeficiency | PTGES2, PTGS2, NFATC1 | PTGS2 2/4885PTGS1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.